Trials / Completed
CompletedNCT00550095
To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
A 24 Week, Multi-centre, Open Label, Non Controlled Study to Assess the Efficacy of Valsartan in Reducing Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 509 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the efficacy of the different dosage forms of Valsartan\[80, 160, and 320 mg\] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | valsartan |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2007-10-26
- Last updated
- 2017-02-23
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT00550095. Inclusion in this directory is not an endorsement.